Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study
Results include -38% reduction in urinary oxalate compared to placebo in Roux-en-Y gastric bypass patients
Favorable safety and tolerability, with frequency and severity of adverse events similar across placebo and active arms
- In the Phase 1b SYNB8802-CP-002 study, SYNB8802 demonstrated a dose-related reduction in urinary oxalate.
- The -38% urinary oxalate reduction observed at the 3x1011 live cell dose three times a day exceeds the level of urinary oxalate reduction (-20%) that has been associated with reduced risk of kidney stones in analyses based on observational data.1
- SYNB8802 was generally well tolerated. There were no serious adverse events (SAEs). All GI-related adverse events (AEs) were mild, and their frequency and severity were similar in the active and placebo group.
“Given the profound need for a medical treatment for enteric hyperoxaluria, we are delighted to demonstrate meaningful reductions in urinary oxalate in the Roux-en-Y gastric bypass patient population,” said
“A subset of enteric patients have repeated kidney stones and life-altering disease that is particularly challenging to manage,” said
The SYNB8802-CP-002 Study
This Phase 1b study was a double-blind, randomized, placebo-controlled, inpatient study evaluating the safety and tolerability of SYNB8802 in subjects with a history of Roux-en-Y gastric bypass surgery. The primary endpoint was safety and tolerability. After a three-day diet and placebo run in, patients were randomized to either placebo or SYNB8802 for a 12-day dosing period. The dosing period included a dose escalation plan with the first six days at the lower dose of 1 × 1011 live cells, followed by six days at the 3 × 1011 live cell dose. Each six-day treatment period included a stepwise increase in dose frequency. To enable a controlled assessment of SYNB8802’s effects on oxalate, patients consumed a controlled diet for the duration of the inpatient stay. Urine was also collected for a 24-hour sample for each patient, each day.
The study enrolled 11 patients; 7 received SYNB8802 and 4 received placebo. SYNB8802 was well tolerated, with no SAEs. The most common AEs were GI-related, mild, and transient. The GI-related AEs occurred at a similar frequency in active and placebo groups. One patient in the placebo group discontinued during dosing due to the need for antibiotics.
Dosing with SYNB8802 was associated with a dose-dependent reduction in urinary oxalate. In a pharmacometric analysis that takes into account all patients’ data, dose level and dose frequency, there was a -28% (-37.2, -18.2) change from baseline in urinary oxalate vs. placebo at the 1x1011 TID dose, and a -38% (-46.4, -28.7) change from baseline in urinary oxalate vs. placebo at the 3x1011 TID dose.
In addition to the completed SYNB8802-CP-002 study, SYNB8802 is also being evaluated in an ongoing, outpatient study (SYNB8802-CP-001). Full results from both studies will be presented at a future medical meeting.
Conference Call & Webcast
Synlogic will host a conference call and live webcast at 8:30 a.m. ET today, December 15, 2022. Joining will be Dr.
About Enteric Hyperoxaluria and SYNB8802
Enteric hyperoxaluria (EH) is a metabolic disease and well-recognized cause of recurrent kidney stones, typically caused by a chronic underlying GI disorder associated with malabsorption, which predisposes patients to excessive absorption of oxalate. Elevated oxalate in the circulation leads to oxalate crystal formation in the kidney, causing excruciating pain and progressive renal damage. There is no FDA-approved treatment for enteric hyperoxaluria. SYNB8802 is a novel, orally administered, non-systemically absorbed drug candidate being developed for the treatment of enteric hyperoxaluria. SYNB8802 was designed using precision genetic engineering of the well-characterized probiotic E. coli Nissle to metabolize oxalate in GI tract, preventing its absorption and resultant crystal formation, lowering levels of urinary oxalate.
1 D’Costa et al. Nephrol Dial Transplant (2020) 1–8.
Synlogic is a clinical-stage biotechnology company developing medicines through its proprietary approach to synthetic biology. Synlogic’s pipeline includes its lead program in phenylketonuria (PKU), which has demonstrated proof of concept with plans to start a pivotal, Phase 3 study in the first half of 2023, and additional novel drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout. The rapid advancement of these potential biotherapeutics, called Synthetic Biotics, has been enabled by Synlogic’s reproducible, target-specific drug design. Synlogic uses programmable, precision genetic engineering of well-characterized probiotics to exert localized activity for therapeutic benefit, with a focus on metabolic and immunological diseases. In addition to its clinical programs, Synlogic has a research collaboration with Roche on the discovery of a novel Synthetic Biotic for the treatment of inflammatory bowel disease or IBD.
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, clinical development plans, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," “look forward,” "estimate," "expect," "intend," “on track,” "plan," "predict" and similar expressions and their variants, as they relate to
|MEDIA CONTACT:||INVESTOR CONTACT:
Berry & Company Public Relations
Kendall Investor Relations
Source: Synlogic, Inc.